Bone-targeted Therapies and Radiopharmaceuticals

Bone-targeted Therapies and Radiopharmaceuticals

Daniel Petrylak, MD discusses alpha-emitting isotope therapy and hormonal chemotherapeutic agents and the survival rate of men with CRPC.

Daniel Petrylak, MD
Yale Cancer Center